"If the USPTO decide to go further, it could take 2-3 years to resolve this"
------
Crikey. If the patent clock is ticking then the two parties need to make a deal. It's that simple.
Its the quick and the dead in this HCV bubble.
It's interesting to note the testesterone charged biocryst are still talking up Phase I trials by end of the year.... playing Russian roulette with shareholder funds but good for us coz they advance the program.
As for the BI collaboration ending as a result of patent uncertainty, the ASX announcement wasn't very clear on the matter....
